^
Association details:
| Biomarker: | MYC amplification |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
51 - A phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC): Genomic sequencing and updated efficacy results
Published date:
03/30/2020
Excerpt:
We also found that PFS (P = 0.0016) for patients on PLD + durva negatively correlated with LRP1B deletions. Patients with MYC amplifications had a lower response (P = 0.0005) and shorter PFS (P = 0.006, HR = 2.889) on the PLD + durva combination..MYC amplification may be central in driving resistance to the combination and has not been previously linked to PLD efficacy.
Secondary therapy:
pegylated liposomal doxorubicin
Trial ID:
